Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled Risdiplam (RO7034067) in Healthy Male Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03036501
Recruitment Status : Completed
First Posted : January 30, 2017
Last Update Posted : October 4, 2018
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This is an open-label, non-randomized study investigating the excretion balance, PK and metabolism of a single oral dose of [14C]-labeled Risdiplam (RO7034067) in healthy male participants. This study will assess the characterize mass balance, routes and rates of elimination of [14C]-labeled Risdiplam (RO7034067), using conventional analytical methods and assess the pharmacokinetics of total drug related [14C]-radioactivity, Risdiplam (RO7034067) and its metabolite(s).

Condition or disease Intervention/treatment Phase
Healthy Drug: [^14C]-Risdiplam Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-label Study Investigating the Excretion Balance, Pharmacokinetics and Metabolism of a Single Oral Dose of [14C]-Labeled RO7034067 in Healthy Male Subjects
Actual Study Start Date : January 3, 2017
Actual Primary Completion Date : February 28, 2017
Actual Study Completion Date : February 28, 2017

Arm Intervention/treatment
Experimental: [^14C]-Risdiplam
Participants will be administered with [^14C]-Risdiplam solution orally under fasted conditions on Day 1.
Drug: [^14C]-Risdiplam
[^14C]-Risdiplam 18 mg oral solution with approximately 0.75 megabecquerel MBq (20 microcuries [μCi]) of [14C]-labeled Risdiplam.




Primary Outcome Measures :
  1. Percentage of Dose Recovered as Total [14C]-radioactivity in Urine [ Time Frame: Day 1 to Day 36 ]
  2. Cumulative Urinary Amount of Total [14C]-Radioactivity in Urine [ Time Frame: Day 1 to Day 36 ]
  3. Percentage of Dose Recovered as Total [14C]-radioactivity in Feces [ Time Frame: Day 1 to Day 36 ]
  4. Maximum Observed Plasma Concentration (Cmax) of Risdiplam [ Time Frame: Day 1 to Day 36 ]
  5. Time to Maximum Observed Plasma Concentration of Risdiplam (Tmax) [ Time Frame: Day 1 to Day 36 ]
  6. Area Under the Plasma Concentration-time Curve from Time 0 to Last Measurable Concentration Time Point (AUC0-last) [ Time Frame: Day 1 to Day 36 ]
  7. Area Under Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) [ Time Frame: Day 1 to Day 36 ]
  8. Apparent Terminal Elimination Half-Life (t1/2) [ Time Frame: Day 1 to Day 36 ]

Secondary Outcome Measures :
  1. Percentage of Participants with Adverse Events [ Time Frame: Up to 10 weeks ]
  2. Percentage of Participants with Laboratory, ECGs, Ophthalmological Assessments, And Vital Signs Abnormalities [ Time Frame: Up to 10 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy male participants, 35 to 65 years of age (inclusive)
  • A body mass index between 18 to 30 kg/m^2 inclusive
  • Agreement to use two methods of contraception, during the treatment period and for at least 4 months after the last dose of study drug. One of the contraceptive methods must be a condom. The second contraceptive method must include one of the following: diaphragm or cervical cap, intra-uterine device or system, or oral, injected or implanted hormonal method of contraception.
  • No intention of donating sperm within 4 months of study drug administration
  • Able to participate and willing to give written informed consent and to comply with the study requirements and restrictions
  • Fluent in the language of the Investigator and study staff and able to communicate with the study staff

Exclusion Criteria:

  • Any condition or disease detected during the medical interview/physical examination that would render the participant unsuitable for the study, place the participant at undue risk or interfere with the ability of the participant to complete the study in the opinion of the Investigator
  • History of any clinically significant gastrointestinal, renal, hepatic, broncho- pulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological or allergic disease, metabolic disorder, hypofertility, cancer or cirrhosis
  • Participants with any clinically significant eye pathology affecting best-corrected visual acuity, or optic neuritis retinal abnormalities on spectral domain - optical coherence tomography and 7-field fundus color photography as assessed by an ophthalmologist
  • History or evidence of (neuro) muscular disorders
  • History or evidence of any medical condition potentially altering the absorption, metabolism or elimination of drugs. Surgical history of the gastrointestinal tract affecting gastric motility or altering the gastrointestinal tract
  • History or evidence of skin disorders, as assessed by a thorough skin examination of the whole body
  • History of malignancy in the past 5 years
  • A history of clinically significant hypersensitivity (e.g., drugs, excipients) or allergic reactions
  • Participants who, in the Investigator's judgment, pose a suicidal or homicidal risk, or any participant with a history of suicidal or homicidal attempts
  • Any major illness within one month before the screening examination or any febrile illness within one week prior to screening and up to study drug administration
  • History or presence of clinically significant ECG abnormalities before study drug administration or cardiovascular disease
  • Clinically significant abnormalities in laboratory test results
  • Positive results on tests for human immunodeficiency virus (HIV)-1 or HIV-2, hepatitis C virus or hepatitis B virus
  • Any suspicion or history of alcohol abuse and/or suspicion of regular consumption of drugs of abuse
  • Confirmed systolic blood pressure (SBP) greater than 150 or less than 90 mmHg, and diastolic blood pressure (DBP) greater than 95 or less than 50 mmHg
  • Confirmed (based on the average of at least 3 consecutive measurements) resting pulse rate greater than 100 or less than 40 bpm
  • Participation in an investigational drug or device study within 90 days prior to screening, as calculated from the day of follow-up from the previous study
  • Smokers who regularly smoke more than 10 cigarettes daily or equivalent tobacco- containing products
  • Dietary restrictions that would prohibit the consumption of standardized meals
  • Use of any prohibited medications and food before study start and during the study
  • Participants under judicial supervision, guardianship or curatorship
  • Infrequent bowel movements (less than once per 24 hours on average)
  • Regular work with ionizing radiation or radioactive material
  • Participants who plan to attempt to father children within 4 months after study drug administration

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03036501


Locations
Layout table for location information
Netherlands
Pra International Group B.V
Groningen, Netherlands, 9728 NZ
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche

Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT03036501     History of Changes
Other Study ID Numbers: BP39122
2016-003461-26 ( EudraCT Number )
First Posted: January 30, 2017    Key Record Dates
Last Update Posted: October 4, 2018
Last Verified: October 2018